Moderna Gains FDA Panel Support for mRNA-1010 Flu Vaccine
CAMBRIDGE, Mass., June 20, 2026 Moderna, Inc. announced a major regulatory milestone for its investigational seasonal influenza vaccine mRNA-1010...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
CAMBRIDGE, Mass., June 20, 2026 Moderna, Inc. announced a major regulatory milestone for its investigational seasonal influenza vaccine mRNA-1010...
CAMBRIDGE, Mass., May 6, 2026 Moderna announced the publication of pivotal Phase 3 clinical safety and efficacy data for...
